Prophylactic tumor vaccination against subsequent tumor challenge depends on effective
crosspriming in vivo. Professional APCs process tumor antigens from whole tumor cells …

Dendritic cells (DCs) that acquired antigen from apoptotic tumor cells are able to induce
major histocompatibility complex (MHC) class Irestricted cytotoxic T lymphocytes and …

Vaccination with tumor extracts circumvents the need to identify specific tumor rejection
antigens and extends the use of active immunotherapy to the vast majority of cancers, in …

Animal studies have shown that vaccination with genetically modified tumor cells or with
dendritic cells (DC) pulsed with tumor antigens are potent strategies to elicit protective …

Recently, cancer immunotherapy has emerged as a therapeutic option for the management
of cancer patients. This is based on the fact that our immune system, once activated, is …

We have reported recently that treatments combining injections of apoptotic bodies from
tumor cells and interleukin 2 led to tumor regression and induced specific protection. In the …

Because of the large preexisting antigenic load and immunosuppressive environment within
a tumor, inducing therapeutically useful antitumor immunity in cancer patients requires the …

Therapeutic vaccines are currently at the forefront of medical innovation. Various endeavors
have been made to develop more consolidated approaches to producing nucleic acid …

Therapeutic cancer vaccines rely on the immune system to eliminate tumor cells. In contrast
to chemotherapy or passive (adoptive) immunotherapies with antibodies or ex vivo …

Dendritic cells are the most potent antigen-presenting cells, and the possibility of their use
for cancer vaccination has renewed the interest in this therapeutic modality. Nevertheless …